Biodesy Announces Corporate Name Change to BlueLight Therapeutics

New company brand identity and Chief Scientific Officer appointment reflect long-term focus on developing small molecule therapeutics that regulate conformation of challenging drug targets   SOUTH SAN FRANCISCO, Calif. – May 27, 2020 – Biodesy Inc. today announced that it has changed its corporate name to BlueLight Therapeutics Inc., effective May 20, 2020, and appointed

Biodesy Announces New CEO and $20 Million Series C Financing to Accelerate Expansion into Biotherapeutics Discovery and Development Market

Former Chief Operations Officer and Delta™ System developer Ariel Notcovich promoted to drive industry adoption of the company’s core biomolecule characterization platform SOUTH SAN FRANCISCO, Calif. – Sept. 10, 2018 – Biodesy, Inc., a next-generation biomolecule characterization company, today announced the promotion of Ariel G. Notcovich to Chief Executive Officer, and the completion of a

Biodesy Delta System Enables Researchers to Discover Novel Mechanism Involved in Infectious Disease

Nature Communications publication highlights new applications for highly-sensitive SHG technology SOUTH SAN FRANCISCO, Calif. – Nov. 20, 2017 – Biodesy, Inc., a leader in next-generation technologies measuring structure and structural changes at the molecular level, today announced that its Delta ® System was used to discover a novel mechanism involved in the earliest steps of viral infection. The collaborative study

Biodesy article cited as one of the most popular in 2015

Biodesy’s article, “Protein Conformational Changes Are Detected and Resolved Site Specifically by Second-Harmonic Generation” published in Biophysical Journal was announced as one of the most popular articles in the journal in 2015 at the Biophysical Society meeting.


Drug Discovery Chemistry 2019

April 09 - 11, 2019 San Diego Convention Center, San Diego, CA

Come visit us at booth 121!

“Fragment-Based Drug Discovery Campaigns with Protein Complexes that Mediate Protein-Protein Interactions”
Presented by Charles Wartchow, Novartis Institutes for Biomedical Research
Tuesday, April 9 at 10:35 am
“New Ways of Targeting K-Ras”
Presented by Frank McCormick, HDF Comprehensive Cancer Center, University of California San Francisco
Plenary Keynote: Thursday, April 11 at 8:55 am
Poster Presentations
“Discrimination of Kinase Conformational States upon Inhibitor Binding by Second-Harmonic Generation”
Presented by Tracy Young, Biodesy
Poster Session A: #A5 (Tuesday, April 9 – Wednesday, April 10)
“Second-Harmonic Generation Based Detection of Ligand-Induced Conformational Changes in STING”
Presented by Serra Elliott, Biodesy
Poster Session B: # B1 (Wednesday, April 10 – Thursday, April 11)
“Second-Harmonic Generation (SHG) – A Novel On-Target and High-Throughput Technology for Small Molecule Screening by Detecting Structural Changes of Target Biomolecules”
Presented by Biodesy
Symposia Session: #S2 (Friday, April 12) Located at the Hard Rock Hotel

The New York Academy of Sciences: Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics

May 22, 2018 The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Please join us at the NYAS on May 22nd for our poster presentation:

Discrimination of kinase conformational states upon inhibitor binding by second harmonic generation

Where we show how SHG can be used to discriminate between conformational states of two full-length kinases and a pseudokinase upon binding to well-characterized tool compounds.

For appointments to discuss scientific or business opportunities please contact us at